Taking Tilray for a year and having a CD4 drop of 100 is not necessarily a failure of antiviral therapy. It is possible that the test reagents are different, the patient’s recent exertion or normal fluctuations. Tirai generally refers to tenofovir disoproxil fumarate tablets + lamivudine tablets + efavirenz, which is a common medication regimen for the treatment of AIDS, which can increase the patient’s CD4 lymphocytes, decrease the viral load, increase the body’s resistance, and reduce the number of opportunistic infections (fever, diarrhea, skin rashes, etc.). 1. Different test reagents: If the test reagents or test strips are different this time, it is possible to have a difference with the last test result. 2. Patient’s recent exertion: If the patient has recently exerted himself/herself, done heavy physical labor, worked at night, or had a cold or diarrhea, etc., it may lead to a decrease in CD4 lymphocytes compared to the previous results. 3. Normal fluctuation: If the patient’s CD4 lymphocytes were 1000 or 800 U/L a year ago and the test lowered them to 900 or 700 U/L, it can be considered as normal fluctuation, and the patient can continue to take antiviral drugs and continue to be monitored. Immunologic treatment failure is considered to have occurred when the CD4 lymphocyte count falls below the pre-treatment value, or falls to half of the highest value, or stays below 100 cells/mm3, regardless of whether or not the virus has been completely suppressed. Patients should be evaluated at this point for a change in antiviral therapy. Patients should take their antiviral medications on a regular basis and have their CD4 lymphocytes and viral load measured regularly to understand the effectiveness of their treatment, and should seek medical attention to adjust their treatment regimen if they find that treatment is failing.